COVID-19 mRNA Vaccines Show Promise in Extending Cancer Patient Survival
A new study published today in Nature indicates that mRNA vaccines, initially developed to combat COVID-19, may significantly improve survival rates for patients undergoing immunotherapy for certain cancers, offering a potential new avenue for cancer treatment.
Researchers at the University of Texas MD Anderson Cancer Center analyzed medical records from 2015 to 2022, comparing 180 patients with stage 3 or 4 lung cancer who received Pfizer or Moderna mRNA vaccines within 100 days of starting immunotherapy to 704 patients who received immunotherapy alone. The study revealed that vaccinated patients experienced a median survival time of 37.3 months, compared to 20.6 months in the unvaccinated group, with 55.7% still alive after three years versus 30.8% in the control group. A similar trend was observed in patients with metastatic melanoma. This finding is particularly significant as cancer remains a leading cause of death worldwide.
The research suggests that mRNA vaccines don’t directly target cancer cells but instead act as an “immune flare,” activating the body’s immune system and making previously undetectable tumors visible to immune cells. Animal studies corroborated these findings, demonstrating that combining mRNA vaccines with immunotherapy helped transform “cold” tumors into ones the immune system could recognize. “We could design an even better non-specific vaccine to mobilise and reset the immune response, in a way that could essentially be a universal, off-the-shelf cancer vaccine for all patients,” stated Dr. Elias Sayour, an oncologist and co-author of the study. Further information on immunotherapy can be found at the National Cancer Institute.
While the study is observational and therefore cannot definitively prove causation, the results are compelling, exceeding the typical survival gains seen with new cancer drugs – a recent review found new drugs increased median overall survival by just 2.8 months. Researchers are now planning randomized controlled trials to confirm these findings and explore the potential for repurposing existing mRNA vaccines, or developing new ones, to enhance cancer treatment. The Nature journal is a leading multidisciplinary science journal.
